Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-087021
Filing Date
2025-06-16
Accepted
2025-06-16 20:32:05
Documents
1
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3498
  Complete submission text file 0000950170-25-087021.txt   5082
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Issuer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O SPERO THERAPEUTICS, INC. 675 MASSACHUSETTS AVE., 14TH FLOOR CAMBRIDGE MA 02139
Business Address
Mahadevia Ankit (Reporting) CIK: 0001720974 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38266 | Film No.: 251051652